[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356632-105":59,"doc-detail-356632-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","homologous-recombination-deficiency-and-hemizygosity-drive-resistance-in-breast-cancer","Homologous recombination deficiency and hemizygosity drive resistance in breast cancer","","The document presents an integrated clinicogenomic analysis of breast cancer patients to determine how germline pathogenic variants and somatic alterations jointly shape tumor evolution and therapy resistance. Germline (g) variants are shown to dictate the evolutionary trajectory toward acquired resistance, with gBRCA2-associated tumors uniquely predisposed to develop acquired RB1 loss-of-function alterations and poor outcomes on frontline CDK4/6 inhibitor combinations. This vulnerability is driven by baseline RB1 hemizygosity and ongoing homologous recombination deficiency, and PARP inhibition outperforms CDK4/6i across models and clinical data.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/homologous-recombination-deficiency-and-hemizygosity-drive-resistance-in-breast-cancer/356632/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/homologous-recombination-deficiency-and-hemizygosity-drive-resistance-in-breast-cancer/356632.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do germline pathogenic variants influence acquired resistance in breast cancer?","Question",{"text":113,"@type":114},"Germline pathogenic variants dictate the evolutionary trajectory toward acquired resistance, shaping which somatic alterations emerge under treatment pressure.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why are gBRCA2-associated tumors particularly prone to acquired RB1 loss-of-function under CDK4/6 inhibition?",{"text":118,"@type":114},"They show a dual mechanism: baseline RB1 hemizygosity lowers the evolutionary barrier to biallelic inactivation, and ongoing homologous recombination deficiency promotes acquisition of RB1 loss-of-function under selective pressure from CDK4/6 inhibitors.",{"name":120,"@type":111,"acceptedAnswer":121},"Which therapy shows better outcomes than CDK4/6 inhibitors in the reported analyses?",{"text":122,"@type":114},"Across multiple independent models and clinical data, PARP inhibition consistently outperformed CDK4/6 inhibitors, suggesting a strategy to intercept RB1-loss trajectories in gBRCA2 carriers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356632,1790182106,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Homologous recombination deficiency and hemizygosity drive resistance in breast cancer  \n\n| [https://doi.org/10.1038/s41586-026-10197-0](https://doi.org/10.1038/s41586-026-10197-0)\u003Cbr>Received: 3 April 2024 Accepted: 23 January 2026 Published online: 4 March 2026 Open access\u003Cbr> Check for updates | Anton Safonov1,2,24, Minna Lee3,4,24, David N. Brown5, Luca Boscolo Bielo1,6, Miika Mehine5,7, Chaitanya Bandlamudi7, Ben O’Leary8, Hong Shao4, Laia Vicente9, Daniel Muldoon5,7, Allen Zhu4, Susana Ros10, Antonio Marra11, Pier Selenica5, Ivan Bieche12,\u003Cbr>Bradley Wubbenhorst13, Emanuela Ferraro1,11, Laura Courtois12, Rania El Botty14,\u003Cbr>MehnajAhmed1, Enrico Moiso6, Julia Ah-Reum An6, MarkT. A. Donoghue7, Marie Will1,4, Fresia Pareja5, Emily Nizialek10, Natalia Lukashchuk10, Eleni Sofianopoulou10, Yuan Liu15, Xin Huang15, Colombe Chappey15, Anna D. Staniszewska10, Dara Ross5, Diana Mandelker5, Marc Ladanyi5,7, Nikolaus Schultz4,7,16, Michael F. Berger5,7, Maurizio Scaltriti17,\u003Cbr>Jorge S. Reis-Filho17, Bob T. Li1,17, Kenneth Offit18, Larry Norton1, Ronglai Shen15,\u003Cbr>Kara N. Maxwell19,20,21, Fergus Couch22, Susan M. Domchek19,20,21, Elisabetta Marangoni12, Sohrab Shah16,23, Mark R. Albertella10, Violeta Serra9,10, Britta Weigelt5, David B. Solit1,4,7, Katherine L. Nathanson13,19,21, Mark E. Robson1,2,18, Nicholas C. Turner8,\u003Cbr>Sarat Chandarlapaty1,2,4 ✉ & Pedram Razavi1,2,6 ✉\u003Cbr>The co-occurrence of germline and somatic oncogenic alterations is frequently observed in breast cancer, yet their combined influence on tumour evolution and therapy resistance remains poorly defined. Through an integrated clinicogenomic analysis of more than 5,800 patients, we show that germline (g) pathogenic variants dictate the evolutionary trajectory of acquired resistance. We specifically find that gBRCA2-associated tumours are uniquely predisposed to develop acquiredRB1 loss-of-function alterations, resulting in poor outcomeson standard-of-care frontline CDK4/6 inhibitor (CDK4/6i) combinations. This vulnerability is driven by a dual mechanism: baseline RB1 hemizygosity (heterozygous loss resulting in a single functional RB1 allele), which lowers the evolutionary barrier tobiallelic inactivation, and ongoing homologous recombination deficiency, which promotes acquisition of RB1 loss-of-function alterations under the selective pressure ofCDK4/6i. Preclinical models from gBRCA2carriers showed near-uniform resistance toCDK4/6i, with consistent post-treatment Rb loss. Across multiple independent models and in our clinical data, PARP inhibition consistently outperformed CDK4/6i. Our findings suggest that prioritizing PARP inhibition ingBRCA2carriers may intercept RB1-loss trajectories and delay resistance. More broadly, we establish a predictive framework for forecasting drug-resistant trajectories based on pre-treatment allelic configuration and mutational signatures. |  |\n| --- | --- | --- |\n| Resistance to anticancer therapy often occurs through a diverse array of |  | Clinically, the expanding landscape of approved targeted and lineage- |\n| genomic mechanisms1–5. The inherent unpredictability of these events |  | directed therapies has introduced considerable uncertainty regarding |\n| challenges the ability to develop proactive strategies topre-empt the |  | the optimal treatment paradigm for patients with breast cancer with |\n| emergence of resistance and improve patient outcomes. The role of |  | certain germline and somatic backgrounds. Given its dominant effect |\n| germline pathogenic variants in predisposition to malignancies and |  | on initial cancer evolution, we posit that the germline background |\n| shaping the initial somatic landscape of tumours is well established6–9. |  | may equally influence tumour behaviour under therapeutic pressure, |\n| This interplay is well exemplified in germline pathogenic variants in |  | effectively directing the evolutionary trajectory of disease progression |\n| certain DNA damage repair genes10–14 that give ri","cbCaitYKSxUY8fDg","https://ap.wps.com/l/cbCaitYKSxUY8fDg","pdf",17149397,35,"English","# Background and rationale\n# Study cohort and genomic methods\n# Germline–somatic interactions driving resistance\n# Mechanistic model: RB1 hemizygosity and HRD under CDK4/6i pressure\n# Therapeutic implications and predictive framework","[{\"question\":\"How do germline pathogenic variants influence acquired resistance in breast cancer?\",\"answer\":\"Germline pathogenic variants dictate the evolutionary trajectory toward acquired resistance, shaping which somatic alterations emerge under treatment pressure.\"},{\"question\":\"Why are gBRCA2-associated tumors particularly prone to acquired RB1 loss-of-function under CDK4/6 inhibition?\",\"answer\":\"They show a dual mechanism: baseline RB1 hemizygosity lowers the evolutionary barrier to biallelic inactivation, and ongoing homologous recombination deficiency promotes acquisition of RB1 loss-of-function under selective pressure from CDK4/6 inhibitors.\"},{\"question\":\"Which therapy shows better outcomes than CDK4/6 inhibitors in the reported analyses?\",\"answer\":\"Across multiple independent models and clinical data, PARP inhibition consistently outperformed CDK4/6 inhibitors, suggesting a strategy to intercept RB1-loss trajectories in gBRCA2 carriers.\"}]","Homologous recombination deficiency and hemizygosity drive resistance in breast cancer | PDF",1790126464,88,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/211e50ae24cc4f13cbb13eeab4690ba8.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4fb402af94a44bf93c2dffae41022c6.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c69ffc8e05e5d3787775253c50089d4.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/822a144a34a047cebe98dd12e56d585d.webp",980,1301]